Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp Further Extends Offer for Orchid Cellmark

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Laboratory Corporation of America has extended its tender offer to acquire all of the outstanding shares of Orchid Cellmark until 5:00 p.m., New York City time, on July 15, 2011.

The offer had been scheduled to expire on June 15. Last month, LabCorp received a request from the US Federal Trade Commission seeking additional information for its review of the $85.4 million acquisition.

LabCorp said today that it is cooperating with the FTC and as a consequence has extended the offer period. It said that as of 6:00 p.m. last night, Orchid shareholders had tendered around 26.5 million shares of common stock representing roughly 88 percent of the firm's outstanding stock.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.